Extraneal is a drug owned by Baxter Healthcare Corp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 19, 2018. Details of Extraneal's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6248726 | Method of peritoneal dialysis using glucose polymer solutions |
Jun, 2018
(6 years ago) |
Expired
|
| US6077836 | Peritoneal dialysis and compositions for use therein |
Jun, 2017
(7 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Extraneal and ongoing litigations to help you estimate the early arrival of Extraneal generic.
Extraneal's Litigations
Extraneal been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6077836. The petitioner , challenged the validity of this patent, with MILNER as the respondent. Click below to track the latest information on how companies are challenging Extraneal's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6248726 | May, 1995 |
Decision
(28 Aug, 2000) | ALSOP et al | |
| US6077836 | January, 1 |
Decision
(14 Sep, 1999) | MILNER | |
US patents provide insights into the exclusivity only within the United States, but Extraneal is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Extraneal's family patents as well as insights into ongoing legal events on those patents.
Extraneal's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Extraneal's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 19, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Extraneal Generics:
There are no approved generic versions for Extraneal as of now.
About Extraneal
Extraneal is a drug owned by Baxter Healthcare Corp. It is used for treating kidney failure by removing waste and extra fluid through the peritoneal membrane. Extraneal uses Icodextrin as an active ingredient. Extraneal was launched by Baxter Hlthcare in 2002.
Approval Date:
Extraneal was approved by FDA for market use on 20 December, 2002.
Active Ingredient:
Extraneal uses Icodextrin as the active ingredient. Check out other Drugs and Companies using Icodextrin ingredient
Treatment:
Extraneal is used for treating kidney failure by removing waste and extra fluid through the peritoneal membrane.
Dosage:
Extraneal is available in solution form for intraperitoneal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 7.5GM/100ML | SOLUTION | Prescription | INTRAPERITONEAL |